Top Markets
Coin of the day
NexgenRx Inc. NexgenRx Inc.

NexgenRx Inc.

NEGXF
Rang in aandelen #29069
NexgenRx Inc., established in 2003 and based in Toronto, Canada, functions as a... NexgenRx Inc., established in 2003 and based in Toronto, Canada, functions as a third-party administrator for health benefit plans. The company's primary role involves efficiently managing, adjudicating, and processing payments for prescription drug, dental, and various other extended healthcare claims for individuals covered by plans offered by its clients across Canada. Beyond core claims handling, NexgenRx offers Health Care Spending Accounts (HCSAs), providing individuals with dedicated funds for their health or dental expenses. Its service portfolio also encompasses individual and aggregate stop-loss insurance products, emergency medical and travel assistance insurance, and a suite of administrative support functions. These administrative services include the collection and disbursement of premiums for life and long-term disability (LTD) coverage, complemented by advanced reporting tools. To enhance convenience, the company facilitates online claims submission and direct deposit services, along with other specialized ancillary services.
Aandeelprijs
$0.325
Laatst gesynchroniseerd: 2026-08-18
Marktkapitalisatie
$23.11M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
62.50%
Land
CA
Handel NexgenRx Inc. (NEGXF)

Categorie

Winst voor NexgenRx Inc. (NEGXF)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van NexgenRx Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van NexgenRx Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
$17.44B -
US
$5.79B -
US
$5.86B -
US
$8.45B -
US
$1.61B -
US